Clinical Trial

Novel Regimens in COVID-19 Treatment

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-05-07.
Status change: Not Yet Recruiting → Recruiting 2020-12-02
Trial Details
NCT Number NCT04382846
Lead Sponsor Tanta University
Conditions COVID, Corona Virus Infection
Enrollment 160 participants
Start Date 2020-05-08
Primary Completion 2030-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2020-12-04